Friday, June 19, 2020 9:55:20 PM
Actually I believe I am conservative. Every Grandkid ha ued their on fund and on this stock. All have my Big Picture view of what lies ahead. They will not be surprised or shocked. They will not sell some of their shares ever.
I have ran the CYDY number mentally probably over 1000 times. I can lay out the super conservative case and the what just happened case.
Either way fortunes will be made. The size of the fortune is all relative to each investor. I have a natural draw to advise young investors.
You kids out there that own CYDY; just hold it. Be very wary about selling it.
Something big is happening. I am thinking it could be the FDA Trials. Someone, somewhere knows what all of us can deduct from past CYDY Cytokine Storm results. You do not need to be a Rhodes Scholar to do this. If it worked with HIV it should work on any flue, Covid-19 included.
The huge buyer pressure could be as simple as the reports this morn that Covid-19 is breaking out in numerous States. That makes a great deal of logical sense. Intelligent buyers draw in all info and make the decision. The past is the past. Don't forget that Rookies. All that counts is CYDY's future.
So what can happen. FDA Approval hits and Nader backs up a truck to collect cash. We then start to have cash flow to do more Cancer Trials.
Cancer? Yes, it's probably 10 times larger, maybe 100X larger market that HIV.
Covid? Huge $$
Buy back shares. Weak shareholders toss their shares in for small $$. Strong shareholders hold. 50 to 100$ on the 2 to 5 year horizon of faster. 500 to 1000$ within 10 years. Lets see who is closer. A 30$ prediction or my 10 year prediction. This is going to be interesting.
I have a Grandson that I am guessing cold have 1,000,000$ in CYDY in 10 years. Think about this in your own case. Teach your children and Grandkids with this stock. They must have some of their own $$ invested.
Stock dividends, cash dividends, stock splits. All will be possible. With cash the world is our oyster.
I have ran the CYDY number mentally probably over 1000 times. I can lay out the super conservative case and the what just happened case.
Either way fortunes will be made. The size of the fortune is all relative to each investor. I have a natural draw to advise young investors.
You kids out there that own CYDY; just hold it. Be very wary about selling it.
Something big is happening. I am thinking it could be the FDA Trials. Someone, somewhere knows what all of us can deduct from past CYDY Cytokine Storm results. You do not need to be a Rhodes Scholar to do this. If it worked with HIV it should work on any flue, Covid-19 included.
The huge buyer pressure could be as simple as the reports this morn that Covid-19 is breaking out in numerous States. That makes a great deal of logical sense. Intelligent buyers draw in all info and make the decision. The past is the past. Don't forget that Rookies. All that counts is CYDY's future.
So what can happen. FDA Approval hits and Nader backs up a truck to collect cash. We then start to have cash flow to do more Cancer Trials.
Cancer? Yes, it's probably 10 times larger, maybe 100X larger market that HIV.
Covid? Huge $$
Buy back shares. Weak shareholders toss their shares in for small $$. Strong shareholders hold. 50 to 100$ on the 2 to 5 year horizon of faster. 500 to 1000$ within 10 years. Lets see who is closer. A 30$ prediction or my 10 year prediction. This is going to be interesting.
I have a Grandson that I am guessing cold have 1,000,000$ in CYDY in 10 years. Think about this in your own case. Teach your children and Grandkids with this stock. They must have some of their own $$ invested.
Stock dividends, cash dividends, stock splits. All will be possible. With cash the world is our oyster.
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
